Encouraging Response to Roche's New MEK-Inhibitor in Melanoma Patients

Cobimetinib (MEK inhibitor), used in combination with Zelboraf (BRAF inhibitor), improved survival without disease progression.
Published Online: July 14, 2014

An experimental drug from Roche helped people with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment, the Swiss drugmaker said on Monday.

Pharmaceutical companies are looking to combination therapy to yield better results and drug cocktails are expected to be crucial as oncologists seek to block cancer on multiple fronts.

Cobimetinib, which is being developed in collaboration with Exelixis Inc, is designed to be used with another Roche drug called Zelboraf for patients with tumors that have a mutation in a gene known as BRAF that allows melanoma cells to grow.

About half of all melanomas have the genetic aberration the drugs target.

Results of a Phase III study involving 495 patients previously untreated for advanced melanoma found those taking both drugs lived significantly longer without their disease worsening compared to those taking Zelboraf alone.

Read the report here: http://reut.rs/1qY6a1s

Source: Reuters

Recommended Articles
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.
Genevieve Kumapley, PharmD, BCOP, discusses the importance of introducing palliative care to patients at the time of diagnosis and explains how a multidisciplinary team approach can affect the utilization of healthcare resources.
During this Insights interview with Genevieve Kumapley, PharmD, BCOP, on the Use of Oral Oncolytics in Palliative Care, part of the Oncology Stakeholders Summit, Spring 2015 series, Dr Kumapley discusses current guidelines for the delivery of palliative care and describes gaps in care.